West Pharmaceutical Services Beheer
Beheer criteriumcontroles 4/4
De CEO West Pharmaceutical Services is Eric Green, benoemd in Apr2015, heeft een ambtstermijn van 11.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.19M, bestaande uit 16.4% salaris en 83.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde $ 63.00M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 9.9 jaar.
Belangrijke informatie
Eric Green
Algemeen directeur
US$7.2m
Totale compensatie
| Percentage CEO-salaris | 16.37% |
| Dienstverband CEO | 11.3yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 9.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jul 28
WST: High Value Injectable Demand And GLP 1 Exposure Will Drive Future Returns
The updated analyst price target for West Pharmaceutical Services has moved higher from $379 to about $404. This reflects analysts’ revised models that incorporate slightly lower revenue growth assumptions, a modest improvement in profit margin expectations, and a somewhat higher future P/E multiple.Seeking Alpha • Jul 24
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift
Summary West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains. Valuation remains rich at 41x forward earnings, but the premium is justified by high-quality compounding, visible growth pillars, and conservative guidance. Read the full article on Seeking AlphaNarratiefupdate • Jul 13
WST: GLP 1 Injectables And On Body Delivery Moves Will Shape Future Returns
The analyst price target for West Pharmaceutical Services has been raised from $358.79 to $379.00, as analysts cite updated models that reflect healthy sector trends, exposure to GLP-1 related volumes, and continued support from recent Outperform ratings and target increases across the Street. Analyst Commentary Recent research commentary on West Pharmaceutical Services has focused on how the company is positioned within injectable drug delivery, its exposure to GLP-1 related volumes, and expectations for execution against updated financial models ahead of upcoming earnings events.Narratiefupdate • Jun 22
WST: Injectable Exposure And High Value Mix Will Shape Balanced Future Returns
Analysts have lifted their implied price target for West Pharmaceutical Services by about $6 to reflect updated fair value assumptions and ongoing confidence in injectable exposure, high value product momentum, and management execution highlighted in recent research. Analyst Commentary Recent research on West Pharmaceutical Services centers on how well the company is positioned in injectable markets and high value product categories, and how that ties into fair value and execution risk.Narratiefupdate • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.Narratiefupdate • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Narratiefupdate • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.Narratiefupdate • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).Narratiefupdate • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.Narratiefupdate • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.Narratiefupdate • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.Narratiefupdate • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.Narratiefupdate • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.Narratiefupdate • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$565m |
| Mar 31 2026 | n/a | n/a | US$543m |
| Dec 31 2025 | US$7m | US$1m | US$494m |
| Sep 30 2025 | n/a | n/a | US$492m |
| Jun 30 2025 | n/a | n/a | US$488m |
| Mar 31 2025 | n/a | n/a | US$467m |
| Dec 31 2024 | US$8m | US$1m | US$493m |
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
Compensatie versus markt: De totale vergoeding ($USD 7.19M ) Eric } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.54M ).
Compensatie versus inkomsten: De vergoeding van Eric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Eric Green (56 yo)
11.3yrs
Tenure
US$7,190,876
Compensatie
Mr. Eric Mark Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its Preside...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.3yrs | US$7.19m | 0.26% $ 63.0m | |
| Senior VP & CFO | 1yr | US$11.80m | 0.0042% $ 1.0m | |
| Chief HR Officer & Senior VP | 10.8yrs | US$1.39m | 0.024% $ 5.9m | |
| SVP & Chief Proprietary Segment Officer | 1.3yrs | US$2.40m | 0.00087% $ 214.9k | |
| VP of Finance & Chief Accounting Officer | 6.3yrs | geen gegevens | 0.0022% $ 533.6k | |
| Senior VP & CTO | 1yr | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP | less than a year | geen gegevens | geen gegevens | |
| Vice President of Global Communications | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy & Corporate Development | 2.8yrs | geen gegevens | 0.00080% $ 197.6k | |
| Senior VP and Chief Quality & Regulatory Officer | 4.3yrs | geen gegevens | geen gegevens | |
| President of Contract Manufacturing | 2.3yrs | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van WST wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.3yrs | US$7.19m | 0.26% $ 63.0m | |
| Independent Director | 12.5yrs | US$344.94k | 0.025% $ 6.1m | |
| Lead Independent Director | 6.5yrs | US$353.84k | 0.0067% $ 1.7m | |
| Independent Director | 1.7yrs | US$330.94k | 0.0019% $ 464.4k | |
| Independent Director | 15.5yrs | US$344.94k | 0.062% $ 15.3m | |
| Independent Director | 15.5yrs | US$329.94k | 0.065% $ 16.0m | |
| Independent Director | 9.9yrs | US$332.14k | 0.016% $ 3.9m | |
| Independent Director | 4.1yrs | US$329.94k | 0.0039% $ 958.5k | |
| Independent Director | 14.5yrs | US$329.94k | 0.045% $ 11.1m | |
| Independent Director | 9.2yrs | US$334.94k | geen gegevens | |
| Honorary Director | no data | geen gegevens | geen gegevens | |
| Independent Director | 5yrs | US$343.84k | 0.0051% $ 1.3m |
9.9yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van WST wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.9 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/06 14:56 |
| Aandelenkoers aan het einde van de dag | 2026/08/06 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
West Pharmaceutical Services, Inc. wordt gevolgd door 28 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Curtis Moiles | BNP Paribas |